

Original Research Article

Insilico Study of Anticorectal cancer properties of some flavonoids and Terpenoids from African Propolis

Abstract:

Propolis, a resinous material produced by honey bees from plant exudates, has long been reported to be used in traditional herbal medicine and is widely consumed as a health aid and immune system booster. The colorectal cancer which is a world health emergency has renewed interest in propolis products worldwide; fortunately, various aspects of the Poly (ADP-ribose) polymerases (PARPs) mechanism are potential targets for propolis compounds. The treatment of CRC has been focus on the tumor site and stage of the disease using chemotherapy or radiotherapy, surgery, hormonal therapy, immunotherapy etc. Apoptosis have been used in preventing damaged cells from developing out but due to secondary mutations in apoptosis-regulating gene, it can distort this order. This work aimed at evaluating the anticancer potential of some flavonoids and terpenoids from African propolis which can inhibit the protein of PARPs therefore preventing the growth of the cancer cell. From the result β - amyryn and naringin showed the best binding affinity and fit at -11.9 kcal/mol and -11.7 kcal/mol respectively which was better than standard drugs Irinotecan -11.2 kcal/mol and Doxorubicin -9.1 kcal/mol with cocrystalline ligand at -11.2 kcal/mol. Other compounds also showed very high binding affinity of more than -9.0 kcal/mol suggesting the propolis compounds as potential anticancer compounds.

Keywords: Molecular docking; Anticorectal cancer; propolis; Poly (ADP-ribose) polymerases (PARPs) ; Flavonoids; Terpenoids,

Introduction:

Cancer is a genetic disease that is said to be multifactorial and also one of the diseases caused by uncontrolled proliferation of abnormal cells division in the body ¹. In comparison with other diseases cancer is complex in nature and therefore has many potential molecular targets for therapeutics development ². Cancer have remained a global health challenge as there are over 200 types of cancer mostly named after the tissue they were found in for the first time like colorectal cancer, breast cancer, skin cancer, lungs cancer, bone cancer etc. Cancer has been reported as one of the significant causes of death in the 21st century ³. World Health Organization (WHO) reported cancer in 2015 as the second leading causes of death of people below 70 years in 91 different countries and the global increase of 18.1 million new cancer cases and 9.6 million cancer related deaths have been reported by Bray et al ⁴. Colorectal cancer (CRC) which is one of the prominent cancer have been reported as the third highest prevalence rate of all cancer in the world and it cases are estimated to reach 2.4 lakhs by 2035 ⁵⁻⁶. The treatment of CRC has

37 been focus on the tumor site and stage of the disease using chemotherapy or radiotherapy,
38 surgery, hormonal therapy, immunotherapy etc.⁷. Apoptosis have been used in preventing
39 damaged cells from developing out but due to secondary mutations in apoptosis-regulating gene,
40 it can distort this order⁸. Natural products have been the bedrock of modern therapeutic medicine
41 as most of drugs have their source from natural products, either as dietary supplement or
42 synthetic analogues⁹. Most flavonoids and other phytochemicals found in nature has been
43 reported to trigger endoplasmic reticulum stress induces tissue damage through apoptosis and
44 necrosis,¹⁰⁻¹¹ modification of some bioactive compounds have been implored to improve
45 bioavailability, specificity and therapeutic effectiveness as well as other variety features which
46 includes implementation of potential chemotherapeutic agents¹²⁻¹⁴. Propolis which is one of the
47 natural products from bees have been acclaimed and reported as a medicinal product, which is a
48 complex resinous product having many compositions of phytochemicals which can change
49 depending on collection site, botanical origin, climate condition, trees around and extraction
50 methods. Propolis has been used ethnomedically in ancient times as a remedy for varieties of
51 disease and recently interest has been renewed in reinvestigating the drug potentials. It has been
52 reported to have antioxidant and antitumor properties¹⁵. Flavonoids which are the most common
53 phytochemicals found in propolis have been reported as phytochemicals having highest
54 antioxidant, antitumor, cytotoxic and chemopreventive properties¹⁶. Some of the flavonoids that
55 have been isolated from African propolis include Acacetin-Algeria, Quercetin-Algeria,
56 Pinocembrin-Algeria and Egypt, Naringenin-Algeria, Chrysin-Algeria and Egypt, Apigenin-
57 Algeria, Kaempferol-Algeria, Macarangin-Kenya and Nigeria, Liquiritigen-Nigeria, Narangin-
58 .etc.¹⁷.

59 Poly (ADP-ribose) polymerases (PARPs) activate DNA repair mechanisms upon stress and
60 cytotoxin-induced DNA damage and inhibition of PARP activity is a lead in cancer drug
61 therapy¹⁸. PARPs-1 functions as a DNA damage sensor and signaling molecule. When it binds
62 with DNA, the activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and
63 polymerizes the ADP-ribose to nuclear acceptor proteins like histones, PARP itself and
64 transcription factors which contribute to inflammatory signal transduction processes. Activation
65 of PARP has been connected in the pathogenesis of stroke and other diseases. Inhibition of
66 PARP by pharmacological agents has proved useful for the therapy of cancer¹⁹. Colorectal
67 cancer is common to both men and women, in terms of morbidity is the third most common
68 cancer, in terms of mortality is rated second. About 10% cases of cancer in the world is
69 colorectal cancer and drugs like cetuximab, Deracizumab and camptosar have been used in the
70 management of colorectal cancer but their effects vary from patient to patient, and the drugs have
71 been reported to have some side effect on the patients. Therefore the search for natural
72 alternative remains sacrosanct²⁰ with the help of molecular docking which have been used in
73 computer aided drug design as a vital tool. However this work will focus on the use of
74 phytochemical compounds (Flavonoids and Terpenoids) from African Propolis in docking on a
75 protein from PARP to know whether it can inhibit its action and also to identify the active site,

76 binding affinity, ligand protein interaction and compare to the result of the docking of standard
77 cancer drugs and the co-crystallized ligand.

78 **Material and Methods**

79 **Protein receptors and ligand retrieval and preparations**

80 The list of some flavonoids and terpenoids from African propolis with proven anti-cancer
81 properties were retrieved from literature¹⁷. Three dimensional (3D) structures of the drugs,
82 flavonoid and terpenoid compounds were retrieved from PubChem web server in simple
83 document format (SDF). They were optimized using Open babel in Python Prescription (version
84 0.8) which converted the ligands energetically to the most stable structures using Merck
85 Molecular Force Field 94 (MMFF94). Similarly, the 3D X-ray crystallographic structure of the
86 Poly (ADP-ribose) polymerases (PARPs) was retrieved from the RCSB protein data bank (PDB)
87 (<https://www.rcsb.org/>) with ID 1UK0. The proteins were then prepared for docking and
88 minimized using the relevant tools in Discovery studio

89 **Molecular Docking**

90 Prior to molecular docking analysis, proteins were pre-processed using Discovery Studio 2020.
91 This step includes the removal of any hetero-groups, other chains and water molecules. The
92 active site of the protein was identified using Discovery studio. Furthermore, the preparation of
93 ligands and receptors in the PDBQT file format were carried out in the AutoDock tool. The
94 molecular docking was carried out using AutoDock Vina to understand the interaction between
95 receptors and ligands. A rigid-flexible docking was performed after setting a grid box
96 surrounding the binding sites of the receptors at exhaustiveness = 8, center x = 5.62, center y = -
97 0.97, center z = 32.52, size x = 20.61, size y = 23.59, size z = 23.74.

98 **Result and Discussion**

99 The result of the molecular docking of some flavonoids, terpenoids, drugs and the cocrystallized
100 ligand on the protein of PARP are shown below below in table 1

101 Fig 1: Protein of the cancer



103 Picture of prepared protein

Picture of Raw protein

104

105

106






107










108









109










110 **Docking Result:**









111 Table 1: The molecular docking result of the compounds, ligand and drugs.





NAME	Pub CID	Structure	Binding affinity
Naringenin	932	 Naringenin	-9.2
Drug(Doxorubicin)	31703		-9.1
Drug(Irinotecan)	60838		-11.2
Pinocembrin	68071	 pinocembrin	-8.9
Betulin	72326		-9.7

β -Amyrin	73145		-11.9
Pinostrobin	73201		-8.8
Pinobanksin	73202		-8.9
Cycloartenol	92110		-11
Lupenone	92158		-10.4
Vestitol	92503		-8.8
Totarol	92783		-10.2
Liquiritigenin	114829		-9.3
Lonchocarpol A	124035		-10.7

6-prenylnaringenin	155094		-9.9
Pimaric acid	220338		-8.9
Lupeol	259846		-10
Torulosol	349315		-7.7
Naringin	442428		-11.7
8-prenylnaringenin	480764		-9.6
Ladanein	3084066		-9.4
Quercetin	5280343		-9.5

Acacetin	5280442	 acacetin	-9.1
Apigenin	5280443	 Apigenin	-9
Calycosin	5280448		-9.4
Kaempferol	5280863	 Kaempferol	-9
Genistein	5280961		-9.4
Chrysin	5281607	 Chrysin	-8.9
Pachypodol	5281677		-8.7
Tectochrysin	5281954		-8.9
Izalpinin	5318691		-8.7

Pectolarigenin	5320438		-9.1
Citadiol	7472055		-8.3
Macarangin	10047854		-10.3
Isonymphaeol B	10070991		-11
Nymphaeol B	10387631		-10.2
Pilosin	12085264		-9.2
Mangiferonic acid	14034474		-11.1
Cupressic acid	44584269		-8.7


Mangiferolic acid	45270099		-11
Ambonic acid	101286242		-11.2
Torulosal	101306776		-8.1
Co-Ligand 2-{3-[4-(4-fluorophenyl)-3,6-dihydro-1(2h)-pyridinyl]propyl}-8-methyl-4(3h)-quinazolinone	135460986		-11.6

112

113 The binding energy of some compounds isolated from the African propolis were shown in table
114 1 which were flavonoids and terpenoids other groups of phytochemicals were not analyzed for,
115 because flavonoids and some terpenoids have been reported to have antioxidant and anticancer
116 properties. The binding affinity score showed that all the compounds have high activity against
117 the cancer protein and some of the compounds have activities higher than that of the control
118 drugs and cocrystallized ligand. The control drug Irinotecan had -11.2 binding activity while
119 Doxorubicin had binding affinity of -9.1. The cocrystallized ligand had binding affinity of -11.6,
120 while most of the compounds have binding activities of -9 and beyond. The most active
121 compound was β - amyrin with binding energy of -11.9 followed by naringin -11.7, ambonic acid
122 -11.2, mangiferonic and mangiferolic acids with binding affinity of -11.1 and -11 respectively.
123 Isonympeol B and cycloartenol have -11 which were all higher than the drug Doxorubicin -9.1.
124 Other compounds were also higher with negative binding energy higher than -9 which showed
125 that most of the compounds have very high activities over the cancer disease. The protein ligand
126 interaction of the compounds with higher activities and that of the cocrystallized ligand and
127 drugs are shown in Fig 2

128 **Protein Ligand interaction**

129 The figures below show the interaction of all the **cocrystallized** ligand, drugs and some
130 phytocompounds that have higher activity with the protein.




131

132 Figure 2.1: the interaction of the drug Irinotecan with the protein

133 From the drug and protein interaction shown above there was a conventional hydrogen bond
134 interaction of ASP 105, ARG 217, MET 229 and TYR 235 while Carbon hydrogen bond
135 interaction at TYR 49, GLN 98, VAL 101, LEU 108, ASP 109, LEU 216, ILE 218, ALA 219,
136 GLY 227, ILE 234 and ASN 245. There were other interactions with weak bonds of van der
137 waals, pi-anion and pi-alkyl.


138



139

140 Figure 2.2: interaction of the protein with β -Amyrin


141 The β - amyrin and protein interaction are shown below there was a conventional hydrogen bond
 142 interaction of ASP 105, while Van der waals interaction at GLN 98, GLU 102, ASN 106, LEU
 143 108, ASP 109, HIS 201, SER 203, ASN 207, LEU 216, TYR 228, TYR 246. There were other
 144 interactions with weak bonds of van der waals, pi-anion and pi-alkyl.



145


146 Fig 2.3: Interaction of the protein with Naringin

147 From the result there was a conventional Hydrogen bond with the amino acid of ASP 105, ARG
148 217, SER 203, ALA 219.




149
150 Fig 2.4: Interaction of the protein with Doxorubicin

151 From the result there was binding interaction of conventional hydrogen bond at SER 203, GLY
152 227, GLU 102 and other bond interaction which include carbon hydrogen bond, van der waal, Pi-
153 akyl, and others at same binding site and amino acid.



154
155 Fig 2.5: Protein interaction with Ambonic acid




Interactions

van der Waals

156

157 Fig 2.6: interaction with Mangiferonic acid




Interactions

van der Waals

Conventional Hydrogen Bond


158

159 Fig 2.7: interaction with Mangiferonic acid




160

161 Fig 2.8: Interaction with Isonympeol A



162

163 Fig 2.9: interaction with Cycloartenol



164

165 Fig 2.10: CocrySTALLIZED Ligand interaction with the protein

166 From the result and interaction it showed that the compounds from propolis bind very well with
167 the protein and also fit perfectly to the protein binding cavity. Most of the compounds have good
168 binding affinity of more than -9 kcal/mol and the amino acids that the binding site from the
169 cocrySTALLINE ligand was also the amino acids that were also bonded by the compounds and drugs
170 thereby showing that the docking was at the binding site.
171

172 Conclusion

173 Honeybee and propolis include a wide range of flavonoids and terpenoids compounds with
174 several biological activities. The presented study screened *in silico* anticancer activities of some
175 flavonoids and terpenoids from African propolis. The study revealed that some of the compounds
176 have strong binding affinity and may inhibit the PARPs development therefore preventing cancer
177 cell growth.
178 .

179

180 References

- 181 1. Sun, Y.S., Zhao, Z., Yang, Z.N., Xu, F., Lu, H.J., Zhu, Z.Y., Shi, W., Jiang, J., Yao, P.P.,
182 Zhu, H.P., 2017. Risk factors and preventions of breast cancer. International Journal of
183 Biological Sciences 13 (11), 1387–1397. <https://doi.org/10.7150/ijbs.21635>.
- 184 2. Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., Yuan, S., 2020. Discovering Anti-
185 Cancer Drugs via Computational Methods. Frontiers in Pharmacology 11, 733.
186 <https://doi.org/10.3389/fphar.2020.00733>.
- 187 3. Yan, B., Yang, W. J., Han, X. Y., and Han, L. H. (2019). Crystal structures and antitumor
188 activity evaluation against gastric carcinoma of two novel coordination polymers. Main
189 Group Chem. 18, 239–246. doi: 10.3233/MGC-180748
- 190 4. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018).
191 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
192 worldwide for 36 cancers in 185 countries. Ca-a Cancer J. Clin. 68, 394–424. doi:
193 10.3322/caac.21492
- 194 5. Siegel, R.L., Miller, K.D., Fuchs, H.E., Jemal, A. Cancer statistics, 2021, CA Cancer J.
195 Clin. 71 (2021) 7–33, <https://doi.org/10.3322/caac.21654>.
- 196 6. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F.
197 Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality
198 worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. (2021) 1–41,
199 <https://doi.org/10.3322/caac.21660>.
- 200 7. Hagan, T.L. Donovan, H.S. Self-advocacy and cancer: a concept analysis, J. Adv. Nurs.
201 69 (10) (2013) 2348–2359, <https://doi.org/10.1111/jan.12084>.

- 202 8. Zhang, X., Li, K., Feng, J., Liu, G., Feng, Y. Blocking the IGF2BP1-promoted glucose
203 metabolism of colon cancer cells via direct de-stabilizing mRNA of the LDHA enhances
204 anticancer effects, *Mol. Ther. Nucleic Acids* (2021),
205 <https://doi.org/10.1016/j.omtn.2020.12.020>
- 206 9. Parmar, F., Patel, C., Highland, H., Pandya, H., George, L.B. Antiproliferative efficacy of
207 kaempferol on cultured daudi cells: an in silico and in vitro study, *Adv. Biol.* 2016 (2016)
208 1–10, <https://doi.org/10.1155/2016/9521756>.
- 209 10. Sharma, V., Janmeda, P. Extraction, isolation and identification of flavonoid from
210 *Euphorbia neriifolia* leaves, *Arab. J. Chem.* 10 (4) (2017) 509–514,
211 <https://doi.org/10.1016/j.arabjc.2014.08.019>.
- 212 11. Liu, H. et al, The natural occurring compounds targeting endoplasmic reticulum stress,
213 *Evid. Based Complement. Alternat. Med.* 2016 (2016),
214 <https://doi.org/10.1155/2016/7831282> 7831282.
- 215 12. Patridge, E., Gareiss, P., Kinch, M.S., Hoyer, D. An analysis of FDA-approved drugs:
216 natural products and their derivatives, *Drug Discov Today.* 21 (2) (2016) 204–207,
217 <https://doi.org/10.1016/j.drudis.2015.01.009>.
- 218 13. Newman, D.J., Cragg, G.M. Natural products as sources of new drugs over the 30 years
219 from 1981 to 2010, *J. Nat. Prod.* 75 (3) (2012) 311–335,
220 <https://doi.org/10.1021/np200906s>.
- 221 14. Mishra, B.B., Tiwari, V.K. Natural products: an evolving role in future drug discovery,
222 *Eur. J. Med. Chem.* 46 (10) (2011) 4769–4807,
223 <https://doi.org/10.1016/j.ejmech.2011.07.057>.
- 224 15. Ugariogu SN, Duru IA, Onwumere FC, Igoli JO. Physicochemical Assessment and Drug
225 Potential of Some Phenylpropanoid and Flavonoid Compounds of Ethyl Acetate Eluate
226 from Umudike Propolis. *Trop J Nat Prod Res.* 2020; 4(12):1208-1214.
227 doi.org/10.26538/tjnpr/v4i12.30
- 228 16. Ugariogu SN, et al. Preliminary Pharmaceutical Active Ingredient and Micronutrient
229 Evaluation of the Leaf of *Corchorus olitorius* (Ahihara). *Nat Ayurvedic Med* 2020, 4(2):
230 000233.
- 231 17. Blicharska N. and Seidel V. Chemical Diversity and Biological Activity of African
232 Propolis © Springer Nature Switzerland AG 2019 A. D. Kinghorn, H. Falk, S. Gibbons,
233 J. Kobayashi, Y. Asakawa, J.-K. Liu (eds.) *Progress in the Chemistry of Organic Natural*
234 *Products*, Vol. 109, https://doi.org/10.1007/978-3-030-12858-6_3
- 235
- 236 18. Lehtio L. et al. Structural basis for inhibitor specificity in human poly (ADP-ribose)
237 polymerase-3 *J Med Chem* 2009; 52 (9):3108-3111
- 238 19. Southan G.J. and Szabo C Poly(ADP-Ribose) Polymerase inhibitors *Current Medicinal*
239 *Chemistry* 2003; 10 (4) 321-340
- 240 20. Ikwu, F.A., Isyaku, Y., Obadawo, B.S, Lawal, H.A and Ajibowu, S.A Insilico design and
241 molecular docking study of CDK-2 inhibitors with potent cytotoxic activity against HCT

242
243

116 colorectal cancer cell line. Journal of Genetic Engineering and Biotechnology 2020;
18 (51)1-12.

UNDER PEER REVIEW